Atriva Therapeutics GmbH, a Tübingen, Germany-based developer of innovative antiviral therapies, raised an additional tranche of seed funding.
The round, which now amounts to €3m in total funding, was co-led by Stichting Participatie Atriva and High-Tech Gründerfonds (HTGF), with participation from Dutch, German and Canadian investors.
Led by Dr. Rainer Lichtenberger, co-founder and CEO, and Prof. Oliver Planz, CSO, Atriva is advancing ATR-002, which targets the indication Influenza in high-risk patients.
This second tranche was provided after that ATR-002 has passed an important preclinical milestone by identifying an optimized formulation approach and confirming the drug as candidate paving the way to clinical development stage.
The current financing will enable the company to enter clinical development by the first half of 2018 and reaching clinical PoC in late 2019.